---
schema_version: "secwatch.filing_event.v1"
accession: "0001806952-25-000007"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:49:29.052768+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma Q2 net loss narrows to $42.7M; raises $100M private placement; LYL314 shows 72% CR rate

## Summary
- Net loss of $42.7M in Q2 2025 vs $45.8M YoY; non-GAAP net loss $37.8M.
- Private placement up to $100M ($50M initial at $13.32/share); pro-forma cash $347M.
- LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL; manageable safety; PiNACLE pivotal trial initiated.
- R&D expenses $34.9M (-13% YoY); G&A expenses $9.8M (-20% YoY).
- Phase 3 trial for 2L LBCL expected by early 2026; LYL314 granted RMAT and Fast Track designations.

## SEC filing metadata
- accession: 0001806952-25-000007
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000180695225000007/0001806952-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000180695225000007/lyel-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001806952-25-000007
- JSON: https://secwatch.observer/filing/0001806952-25-000007.json
- Plain text: https://secwatch.observer/filing/0001806952-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.